BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

449 related articles for article (PubMed ID: 17637754)

  • 1. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer.
    Attard G; Clark J; Ambroisine L; Fisher G; Kovacs G; Flohr P; Berney D; Foster CS; Fletcher A; Gerald WL; Moller H; Reuter V; De Bono JS; Scardino P; Cuzick J; Cooper CS;
    Oncogene; 2008 Jan; 27(3):253-63. PubMed ID: 17637754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TMPRSS2-ERG gene fusion status in minute (minimal) prostatic adenocarcinoma.
    Albadine R; Latour M; Toubaji A; Haffner M; Isaacs WB; A Platz E; Meeker AK; Demarzo AM; Epstein JI; Netto GJ
    Mod Pathol; 2009 Nov; 22(11):1415-22. PubMed ID: 19734849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer.
    Laxman B; Tomlins SA; Mehra R; Morris DS; Wang L; Helgeson BE; Shah RB; Rubin MA; Wei JT; Chinnaiyan AM
    Neoplasia; 2006 Oct; 8(10):885-8. PubMed ID: 17059688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.
    Hermans KG; van Marion R; van Dekken H; Jenster G; van Weerden WM; Trapman J
    Cancer Res; 2006 Nov; 66(22):10658-63. PubMed ID: 17108102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Morphological features of TMPRSS2-ERG gene fusion prostate cancer.
    Mosquera JM; Perner S; Demichelis F; Kim R; Hofer MD; Mertz KD; Paris PL; Simko J; Collins C; Bismar TA; Chinnaiyan AM; Rubin MA
    J Pathol; 2007 May; 212(1):91-101. PubMed ID: 17385188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues.
    Tu JJ; Rohan S; Kao J; Kitabayashi N; Mathew S; Chen YT
    Mod Pathol; 2007 Sep; 20(9):921-8. PubMed ID: 17632455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer.
    Mehra R; Tomlins SA; Yu J; Cao X; Wang L; Menon A; Rubin MA; Pienta KJ; Shah RB; Chinnaiyan AM
    Cancer Res; 2008 May; 68(10):3584-90. PubMed ID: 18483239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States.
    Mosquera JM; Mehra R; Regan MM; Perner S; Genega EM; Bueti G; Shah RB; Gaston S; Tomlins SA; Wei JT; Kearney MC; Johnson LA; Tang JM; Chinnaiyan AM; Rubin MA; Sanda MG
    Clin Cancer Res; 2009 Jul; 15(14):4706-11. PubMed ID: 19584163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement.
    Yoshimoto M; Joshua AM; Chilton-Macneill S; Bayani J; Selvarajah S; Evans AJ; Zielenska M; Squire JA
    Neoplasia; 2006 Jun; 8(6):465-9. PubMed ID: 16820092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel four-color fluorescence in situ hybridization assay for the detection of TMPRSS2 and ERG rearrangements in prostate cancer.
    Qu X; Randhawa G; Friedman C; O'Hara-Larrivee S; Kroeger K; Dumpit R; True L; Vakar-Lopez F; Porter C; Vessella R; Nelson P; Fang M
    Cancer Genet; 2013; 206(1-2):1-11. PubMed ID: 23352841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TMPRSS2:ETS fusions and clinicopathologic characteristics of prostate cancer patients from Eastern China.
    Dong J; Xiao L; Sheng L; Xu J; Sun ZQ
    Asian Pac J Cancer Prev; 2014; 15(7):3099-103. PubMed ID: 24815454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relative 8q gain predicts disease-specific survival irrespective of the TMPRSS2-ERG fusion status in diagnostic biopsies of prostate cancer.
    Barros-Silva JD; Ribeiro FR; Rodrigues A; Cruz R; Martins AT; Jerónimo C; Henrique R; Teixeira MR
    Genes Chromosomes Cancer; 2011 Aug; 50(8):662-71. PubMed ID: 21584900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence and prognostic significance of TMPRSS2-ERG gene fusion in lymph node positive prostate cancers.
    Fleischmann A; Saramäki OR; Zlobec I; Rotzer D; Genitsch V; Seiler R; Visakorpi T; Thalmann GN
    Prostate; 2014 Dec; 74(16):1647-54. PubMed ID: 25252136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer.
    Pflueger D; Rickman DS; Sboner A; Perner S; LaFargue CJ; Svensson MA; Moss BJ; Kitabayashi N; Pan Y; de la Taille A; Kuefer R; Tewari AK; Demichelis F; Chee MS; Gerstein MB; Rubin MA
    Neoplasia; 2009 Aug; 11(8):804-11. PubMed ID: 19649210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In situ sequencing identifies TMPRSS2-ERG fusion transcripts, somatic point mutations and gene expression levels in prostate cancers.
    Kiflemariam S; Mignardi M; Ali MA; Bergh A; Nilsson M; Sjöblom T
    J Pathol; 2014 Oct; 234(2):253-61. PubMed ID: 24931216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome.
    Yoshimoto M; Joshua AM; Cunha IW; Coudry RA; Fonseca FP; Ludkovski O; Zielenska M; Soares FA; Squire JA
    Mod Pathol; 2008 Dec; 21(12):1451-60. PubMed ID: 18500259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer.
    Leyten GH; Hessels D; Jannink SA; Smit FP; de Jong H; Cornel EB; de Reijke TM; Vergunst H; Kil P; Knipscheer BC; van Oort IM; Mulders PF; Hulsbergen-van de Kaa CA; Schalken JA
    Eur Urol; 2014 Mar; 65(3):534-42. PubMed ID: 23201468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion.
    Tsourlakis MC; Weigand P; Grupp K; Kluth M; Steurer S; Schlomm T; Graefen M; Huland H; Salomon G; Steuber T; Wilczak W; Sirma H; Simon R; Sauter G; Minner S; Quaas A
    Am J Pathol; 2014 Mar; 184(3):609-17. PubMed ID: 24378408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients.
    Magi-Galluzzi C; Tsusuki T; Elson P; Simmerman K; LaFargue C; Esgueva R; Klein E; Rubin MA; Zhou M
    Prostate; 2011 Apr; 71(5):489-97. PubMed ID: 20878952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model.
    Mertz KD; Setlur SR; Dhanasekaran SM; Demichelis F; Perner S; Tomlins S; Tchinda J; Laxman B; Vessella RL; Beroukhim R; Lee C; Chinnaiyan AM; Rubin MA
    Neoplasia; 2007 Mar; 9(3):200-6. PubMed ID: 17401460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.